John Vansavage, MD
Urology · Mayfield, KYNPI 1467457945
Payments from drug & device makers
What this record shows
24 manufacturers reported payments, led by Procept Biorobotics Corporation at 34.6% of the total. Reporting peaked in 2024 at $3,308 and has fallen 92.2% since, to $259 in 2025.
Across 143 payments — averaging $65.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$3K
- Boston Scientific$3K
- Axonics, Inc.$2K
- 180 Medical, Inc.$233
- Lumenis, Inc$185
- Astellas Pharma US Inc$184
- plus $828 from 18 others
What the payments were for
- Travel & lodging$5,42358%
- Food & beverage$3,91842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 20 | $3,230 |
| Boston Scientific | 33 | $2,999 |
| Axonics, Inc. | 25 | $1,682 |
| 180 Medical, Inc. | 12 | $233 |
| Lumenis, Inc | 4 | $185 |
| Astellas Pharma US Inc | 8 | $184 |
| Johnson & Johnson(2 entities) | 4 | $119 |
| Tolmar Pharmaceuticals, Inc. | 6 | $116 |
| Sumitomo Pharma America, Inc. | 3 | $78 |
| Endo Pharmaceuticals Inc. | 4 | $75 |
| Urogen Pharma, Inc. | 3 | $63 |
| Merck | 3 | $60 |
| Coloplast | 3 | $54 |
| Bayer | 3 | $53 |
| Myriad Genetic Laboratories, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Olympus America Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Biomerieux Inc | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| ABC Home Medical Supply, Inc. | 1 | $14 |
| Palette Life Sciences, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$2,737
- Bulkamid$1,067
- Axonics r-SNM System$1,067
- SOLYX$861
- GENERAL BPH$753
- AMS$437
- GENERAL KIDNEY STONE DISEASE$201
- AMS 700 CXR RTE KIT$127
How this compares
$9,341 in reported general payments places this provider in the 85th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 260 | $157,941 |
| Potassium Citrate ErPotassium Citrate | 152 | $14,488 |
| Mirabegron ErMirabegron | 14 | $10,440 |
| Oxybutynin Chloride ErOxybutynin Chloride | 445 | $9,729 |
| Tamsulosin Hcl | 730 | $7,771 |
| Estradiol | 82 | $5,428 |
| Finasteride | 382 | $3,629 |
| Testosterone Cypionate | 45 | $2,137 |
| NitrofurantoinNitrofurantoin Macrocrystal | 56 | $1,844 |
| Solifenacin Succinate | 29 | $1,677 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 99 | $1,489 |
| Trospium Chloride | 21 | $1,427 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $325 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 69 | $246 |
| Ketorolac Tromethamine | 24 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $184 | $157,941260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 urology providers in Kentucky.
Other urology in Mayfield
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
- Stephen MonnigLexington$18K
- Kellen ChoiLouisville$17K
- Rosa ParkLouisville$16K
- Brian ShayCrestview Hills$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.